TY - JOUR
T1 - Transcriptome profiling of antimicrobial resistance in Pseudomonas aeruginosa
AU - Khaledi, Ariane
AU - Schniederjans, Monika
AU - Pohl, Sarah
AU - Rainer, Roman
AU - Bodenhofer, Ulrich
AU - Xia, Boyang
AU - Klawonn, Frank
AU - Bruchmann, Sebastian
AU - Preusse, Matthias
AU - Eckweiler, Denitsa
AU - Dötsch, Andreas
AU - Häussler, Susanne
N1 - Funding Information:
We thank Iris F. Chaberny (Hanover Medical School, Hanover, Germany), Daniel Jonas (Freiburg University Medical Centre, Freiburg, Germany), Wolfgang Witte and Yvonne Pfeifer (Robert-Koch-Institute, Wernigerode, Germany), and Martin Kaase and Sören Gatermann (National Reference Laboratory for Multidrug-Resistant Gram-Negative Bacteria, Bochum, Germany) for providing us with clinical P. aeruginosa isolates. Furthermore, we are grateful to Ole Lund and Rolf Kaas (Technical University of Denmark, Lyngby, Denmark) for kindly providing us with a protocol describing their k-mer methodology for the calculation of phylogenetic distances prior to publication. We also thank Robert Geffers and the Genome Analytics Research Group (Helmholtz Centre for Infection Research, Braunschweig, Germany) for performing the Illumina sequencing and Klaus Hornischer (Helmholtz Centre for Infection Research, Braunschweig, Germany) for establishing the Bactome database. TWINCORE is a joint venture between the Helmholtz Centre for Infection Research, Braunschweig, Germany, and the Hanover Medical School, Hanover, Germany. S.H., A.K., and M.S. conceived and designed the experiments. A.K. and M.S. performed the experiments. D.E. and A.D. provided tools for data analysis. A.K., M.S., S.P., U.B., R.R., B.X., S.B., F.K., and M.P. analyzed the data. S.H., A.K., and M.S. wrote the paper. Financial support from the European Research Council (http://erc.europa.eu/) (starter grant 260276) is gratefully acknowledged. M.S. was funded by the Ph.D. Program "Infection Biology" of the Hanover Biomedical Research School. A.K., S.P., and S.B. were supported by the Helmholtz International Graduate School for Infection Research under contract number VH-GS-202. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This work, including the efforts of Sebastian Bruchmann, Matthias Preusse, Denitsa Eckweiler, Andreas Dötsch, and Susanne Häussler, was funded by EC | European Research Council (ERC) (260276). This work, including the efforts of Ariane Khaledi, Sarah Pohl, and Sebastian Bruchmann, was funded by Helmholtz-Gemeinschaft (Helmholtz Association) (VH-GS-202).
Publisher Copyright:
Copyright © 2016, American Society for Microbiology. All Rights Reserved.
PY - 2016/8
Y1 - 2016/8
N2 - Emerging resistance to antimicrobials and the lack of new antibiotic drug candidates underscore the need for optimization of current diagnostics and therapies to diminish the evolution and spread of multidrug resistance. As the antibiotic resistance status of a bacterial pathogen is defined by its genome, resistance profiling by applying next-generation sequencing (NGS) technologies may in the future accomplish pathogen identification, prompt initiation of targeted individualized treatment, and the implementation of optimized infection control measures. In this study, qualitative RNA sequencing was used to identify key genetic determinants of antibiotic resistance in 135 clinical Pseudomonas aeruginosa isolates from diverse geographic and infection site origins. By applying transcriptome-wide association studies, adaptive variations associated with resistance to the antibiotic classes fluoroquinolones, aminoglycosides, and β-lactams were identified. Besides potential novel biomarkers with a direct correlation to resistance, global patterns of phenotype-associated gene expression and sequence variations were identified by predictive machine learning approaches. Our research serves to establish genotype-based molecular diagnostic tools for the identification of the current resistance profiles of bacterial pathogens and paves the way for faster diagnostics for more efficient, targeted treatment strategies to also mitigate the future potential for resistance evolution.
AB - Emerging resistance to antimicrobials and the lack of new antibiotic drug candidates underscore the need for optimization of current diagnostics and therapies to diminish the evolution and spread of multidrug resistance. As the antibiotic resistance status of a bacterial pathogen is defined by its genome, resistance profiling by applying next-generation sequencing (NGS) technologies may in the future accomplish pathogen identification, prompt initiation of targeted individualized treatment, and the implementation of optimized infection control measures. In this study, qualitative RNA sequencing was used to identify key genetic determinants of antibiotic resistance in 135 clinical Pseudomonas aeruginosa isolates from diverse geographic and infection site origins. By applying transcriptome-wide association studies, adaptive variations associated with resistance to the antibiotic classes fluoroquinolones, aminoglycosides, and β-lactams were identified. Besides potential novel biomarkers with a direct correlation to resistance, global patterns of phenotype-associated gene expression and sequence variations were identified by predictive machine learning approaches. Our research serves to establish genotype-based molecular diagnostic tools for the identification of the current resistance profiles of bacterial pathogens and paves the way for faster diagnostics for more efficient, targeted treatment strategies to also mitigate the future potential for resistance evolution.
KW - Aminoglycosides/pharmacology
KW - Anti-Bacterial Agents/pharmacology
KW - Drug Resistance, Multiple, Bacterial/genetics
KW - Fluoroquinolones/pharmacology
KW - Gene Expression Profiling/methods
KW - High-Throughput Nucleotide Sequencing/methods
KW - Humans
KW - Microbial Sensitivity Tests/methods
KW - Pseudomonas Infections/drug therapy
KW - Pseudomonas aeruginosa/drug effects
KW - Transcriptome/genetics
KW - beta-Lactams/pharmacology
UR - http://www.scopus.com/inward/record.url?scp=84979529676&partnerID=8YFLogxK
U2 - 10.1128/AAC.00075-16
DO - 10.1128/AAC.00075-16
M3 - Article
C2 - 27216077
AN - SCOPUS:84979529676
SN - 0066-4804
VL - 60
SP - 4722
EP - 4733
JO - Antimicrobial Agents and Chemotherapy
JF - Antimicrobial Agents and Chemotherapy
IS - 8
ER -